Nuveen LLC boosted its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,975,317 shares of the company’s stock after purchasing an additional 27,199 shares during the quarter. Nuveen LLC owned about 0.89% of Elevance Health worth $692,447,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of ELV. Rossby Financial LCC grew its stake in Elevance Health by 110.0% in the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after acquiring an additional 44 shares during the period. J.Safra Asset Management Corp bought a new stake in shares of Elevance Health during the fourth quarter valued at approximately $32,000. ORG Partners LLC increased its holdings in shares of Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares in the last quarter. Dorato Capital Management bought a new stake in shares of Elevance Health during the fourth quarter valued at approximately $41,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in shares of Elevance Health during the fourth quarter valued at approximately $38,000. 89.24% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts have recently commented on the company. Evercore reissued a “hold” rating on shares of Elevance Health in a research note on Tuesday, May 19th. Truist Financial increased their price objective on Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Guggenheim increased their price objective on Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Finally, Robert W. Baird increased their price objective on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $416.11.
Elevance Health Price Performance
NYSE:ELV opened at $399.64 on Friday. The firm has a market capitalization of $86.79 billion, a price-to-earnings ratio of 17.00, a P/E/G ratio of 2.29 and a beta of 0.67. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $426.98. The stock has a fifty day moving average of $364.53 and a 200 day moving average of $344.44. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48.
Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter last year, the business posted $11.97 earnings per share. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts expect that Elevance Health, Inc. will post 26.93 EPS for the current fiscal year.
Elevance Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s payout ratio is currently 29.26%.
Elevance Health Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Featured Articles
- Five stocks we like better than Elevance Health
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
